Intervention
spironolactone
ClinicalTrials.gov intervention label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov intervention label, found in 13 distinct published trials. Registry interventions may represent drugs, devices, procedures or other study activities. A matched term or study association does not establish product equivalence, efficacy or regulatory approval.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
13 shownEfficacy of Spironolactone Combined With Antihypertensive Drugs in Patients With Primary AldosteronismNCT07137364 · 2022-05-01
RECRUITINGSpironolactone Safety in Dialysis PatientsNCT00328809 · 2013-06-30
WITHDRAWNPatiromer in the Treatment of Hyperkalemia in Patients With Hypertension and Diabetic Nephropathy (AMETHYST-DN)NCT01371747 · 2011-06-01
COMPLETEDEvaluation of Patiromer Titration in Heart Failure Patients With Chronic Kidney DiseaseNCT01130597 · 2010-05-01
COMPLETEDThe Effect of Spironolactone on Blood Pressure in Type-2 Diabetics With Resistant HypertensionNCT01062763 · 2010-03-01
COMPLETEDSpironolactone Versus Amiloride as an Add on Agent in Resistant HypertensionNCT00709137 · 2008-10-01
WITHDRAWNImportance of Aldosterone in the Pathogenesis of Hypertensive Heart DiseaseNCT00865501 · 2008-03-01
COMPLETEDEffect of Aldosterone on Energy Starvation in Heart FailureNCT00574119 · 2007-12-01
COMPLETEDAddition of Spironolactone in Patients With Resistant Arterial HypertensionNCT00524615 · 2007-09-01
UNKNOWNEffect of Betablocker or Aldosterone Antagonist Therapy on Patients With Liver CirrhosisNCT00332904 · 2006-08-01
UNKNOWNLarger Dose of Spironolactone for the Treatment of Patients With Nonischemic CardiomyopathyNCT00125437 · 2005-09-01
TERMINATEDSpironolactone for Reducing Proteinuria in Diabetic NephropathyNCT00498537 · 2003-01-01
COMPLETEDExamining the Effect of Different Diuretics on Fluid Retention in Diabetics Treated With Rosiglitazone.NCT00306696 · 2002-10-01
COMPLETEDCommon conditions
Hypertension4Diabetes Mellitus2Heart Failure2Arterial Hypertension1Chronic Kidney Disease1Congestive Heart Failure1Diabetic Nephropathy1End Stage Renal Disease1Heart Failure, Congestive1Hyperkalemia1Hypertension, Resistant to Conventional Therapy1Liver Cirrhosis1Nonischemic Dilated Cardiomyopathy1Portal Hypertension1Primary Aldosteronism1Primary Hypertension1
Leading sponsors
Relypsa, Inc.
2
GlaxoSmithKline
1
Hebei Medical University
1
Hvidovre University Hospital
1
Ib Abildgaard Jacobsen
1
Jan Vaclavík
1
State University of New York - Upstate Medical University
1
Third Military Medical University
1
University of Erlangen-Nürnberg Medical School
1
US Department of Veterans Affairs
1
VA Salt Lake City Health Care System
1
Vanderbilt University
1
Trial status mix
COMPLETED7
UNKNOWN2
WITHDRAWN2
RECRUITING1
TERMINATED1
Phase mix
PHASE45
NA3
PHASE22
PHASE32
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.